JP2016528236A - 生物学的試料において改善された性能を有するｔｉｍｐ２のためのアッセイ - Google Patents

生物学的試料において改善された性能を有するｔｉｍｐ２のためのアッセイ Download PDF

Info

Publication number
JP2016528236A
JP2016528236A JP2016533450A JP2016533450A JP2016528236A JP 2016528236 A JP2016528236 A JP 2016528236A JP 2016533450 A JP2016533450 A JP 2016533450A JP 2016533450 A JP2016533450 A JP 2016533450A JP 2016528236 A JP2016528236 A JP 2016528236A
Authority
JP
Japan
Prior art keywords
antibody
monoclonal antibody
seq
human
timp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528236A5 (enExample
Inventor
ヴィジャイェンドラン，ラヴィ，エー．
ヴェンカタスッバラオ，スリヴァトゥサ
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2016528236A publication Critical patent/JP2016528236A/ja
Publication of JP2016528236A5 publication Critical patent/JP2016528236A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016533450A 2013-08-07 2014-08-07 生物学的試料において改善された性能を有するｔｉｍｐ２のためのアッセイ Pending JP2016528236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863073P 2013-08-07 2013-08-07
US61/863,073 2013-08-07
PCT/US2014/050195 WO2015021308A1 (en) 2013-08-07 2014-08-07 Assays for timp2 having improved performance in biological samples

Publications (2)

Publication Number Publication Date
JP2016528236A true JP2016528236A (ja) 2016-09-15
JP2016528236A5 JP2016528236A5 (enExample) 2017-08-10

Family

ID=52461941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533450A Pending JP2016528236A (ja) 2013-08-07 2014-08-07 生物学的試料において改善された性能を有するｔｉｍｐ２のためのアッセイ

Country Status (12)

Country Link
US (2) US9879091B2 (enExample)
EP (2) EP3617234A1 (enExample)
JP (1) JP2016528236A (enExample)
KR (1) KR20160039682A (enExample)
CN (1) CN105531291A (enExample)
AU (1) AU2014305883A1 (enExample)
BR (1) BR112016002685A2 (enExample)
CA (1) CA2920521A1 (enExample)
EA (1) EA201690185A1 (enExample)
HK (1) HK1222180A1 (enExample)
MX (1) MX2016001573A (enExample)
WO (1) WO2015021308A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533695A (ja) * 2016-10-28 2019-11-21 アスチュート メディカル，インコーポレイテッド 腎機能の改善のためのｔｉｍｐ−２に対する抗体の使用
JP2020516603A (ja) * 2017-04-05 2020-06-11 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2017117490A1 (en) * 2015-12-30 2017-07-06 Bio-Rad Laboratories, Inc. Droplet assay system with automatic calibration
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2018006049A1 (en) * 2016-06-30 2018-01-04 The Research Foundation For The State University Of New York Compositions and methods for modifying activity of extracellular mmp-2
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN112384807A (zh) 2018-05-24 2021-02-19 雷尼布斯治疗公司 治疗有风险患有肾损伤和肾衰竭的患者的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698671A (en) * 1989-03-21 1997-12-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metalloproteinase peptides
JP2002507725A (ja) * 1998-03-16 2002-03-12 クイデル コーポレイション イムノアッセイデバイスおよび方法
WO2007048102A2 (en) * 2005-10-18 2007-04-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Angio-inhibitory peptides derived from human timp-2
JP2008516593A (ja) * 2004-10-15 2008-05-22 ガラパゴス・ナムローゼ・フェンノートシャップ 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459004A (en) 1891-09-08 Box for steaming cops
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5166051A (en) 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU8489698A (en) * 1997-07-16 1999-02-10 Charm Sciences, Inc. A test device and method for detecting the presence of a residue analyte in a sample
US7214542B2 (en) * 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
WO2004096832A2 (en) * 2003-04-29 2004-11-11 Children's Medical Center Corporation Novel antiangiogenic peptides
EP1662257A4 (en) * 2003-08-11 2007-12-12 Kyowa Medex Co Ltd TOOL FOR MEASURING MEASURING OBJECT, MEASURING DEVICE AND MEASURING METHOD
US20100009462A1 (en) * 2004-07-28 2010-01-14 Andreas Christ Timp-2 as target/marker of beta cell failure
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8900881B2 (en) * 2008-12-30 2014-12-02 Jin Po Lee Quantitative analyte assay device and method
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CA2794721A1 (en) * 2010-03-31 2011-10-13 Sekisui Medical Co., Ltd. Assay utilizing immunochromatography, immunochromatographic test strip, and assay reagent kit for immunochromatography

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698671A (en) * 1989-03-21 1997-12-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metalloproteinase peptides
JP2002507725A (ja) * 1998-03-16 2002-03-12 クイデル コーポレイション イムノアッセイデバイスおよび方法
JP2008516593A (ja) * 2004-10-15 2008-05-22 ガラパゴス・ナムローゼ・フェンノートシャップ 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法
WO2007048102A2 (en) * 2005-10-18 2007-04-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Angio-inhibitory peptides derived from human timp-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 34, JPN6018015860, 2000, pages 26416 - 26422, ISSN: 0004163090 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533695A (ja) * 2016-10-28 2019-11-21 アスチュート メディカル，インコーポレイテッド 腎機能の改善のためのｔｉｍｐ−２に対する抗体の使用
JP7100030B2 (ja) 2016-10-28 2022-07-12 アスチュート メディカル，インコーポレイテッド 腎機能の改善のためのｔｉｍｐ－２に対する抗体の使用
JP2020516603A (ja) * 2017-04-05 2020-06-11 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ
JP7315466B2 (ja) 2017-04-05 2023-07-26 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ

Also Published As

Publication number Publication date
EA201690185A1 (ru) 2016-07-29
BR112016002685A2 (pt) 2018-01-30
EP3617234A1 (en) 2020-03-04
EP3030582A1 (en) 2016-06-15
KR20160039682A (ko) 2016-04-11
US20160297893A1 (en) 2016-10-13
MX2016001573A (es) 2016-09-07
AU2014305883A1 (en) 2016-02-25
CA2920521A1 (en) 2015-02-12
HK1222180A1 (zh) 2017-06-23
EP3030582A4 (en) 2017-05-17
US10457744B2 (en) 2019-10-29
CN105531291A (zh) 2016-04-27
US20180162953A1 (en) 2018-06-14
WO2015021308A1 (en) 2015-02-12
US9879091B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
JP7277623B2 (ja) 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
US10457744B2 (en) Assays for TIMP2 having improved performance in biological samples
JP2023145528A (ja) 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ
JP2021509120A (ja) Ｃｃｌ１４に関する抗体およびアッセイ
US20210024644A1 (en) N-cadherin binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203